(Q40438125)

20 September 2017

title

Outcomes of Clostridium difficile-associated disease treated with metronidazole or vancomycin before and after the emergence of NAP1/027. (English)

1 reference

20 September 2017

main subject

Clostridium difficile

0 references

1 reference

1 reference

2

Louis Valiquette

1 reference

20 September 2017

Jacques Pépin

1

1 reference

20 September 2017

Sandra Gagnon

series ordinal

3

1 reference

20 September 2017

Sophie Routhier

series ordinal

4

1 reference

20 September 2017

Isabel Brazeau

series ordinal

5

1 reference

20 September 2017

language of work or name

English

0 references

publication date

26 September 2007

1 reference

The American Journal of Gastroenterology

20 September 2017

published in

1 reference

20 September 2017

volume

102

1 reference

20 September 2017

issue

12

1 reference

20 September 2017

page(s)

2781-2788

1 reference

Clostridium difficile-associated diarrhea in a region of Quebec from 1991 to 2003: a changing pattern of disease severity

20 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2007.01539.X

Mortality attributable to nosocomial Clostridium difficile-associated disease during an epidemic caused by a hypervirulent strain in Quebec

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2007.01539.X

A predominantly clonal multi-institutional outbreak of Clostridium difficile-associated diarrhea with high morbidity and mortality

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2007.01539.X

An epidemic, toxin gene-variant strain of Clostridium difficile

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2007.01539.X

Clostridium difficile ribotype 027, toxinotype III, the Netherlands

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2007.01539.X

Prospective randomised trial of metronidazole versus vancomycin for Clostridium-difficile-associated diarrhoea and colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2007.01539.X

Comparison of vancomycin, teicoplanin, metronidazole, and fusidic acid for the treatment of Clostridium difficile-associated diarrhea

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2007.01539.X

Clinical practice. Antibiotic-associated diarrhea

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2007.01539.X

Clostridium difficile colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2007.01539.X

Comparison of two oral formulations of vancomycin for treatment of diarrhoea associated with Clostridium difficile

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2007.01539.X

Narrative review: the new epidemic of Clostridium difficile-associated enteric disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2007.01539.X

Increasing risk of relapse after treatment of Clostridium difficile colitis in Quebec, Canada

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2007.01539.X

Clostridium difficile infection in hospitals: a brewing storm

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2007.01539.X

Impact of aging on gastrointestinal mucosal immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2007.01539.X

Faecal metronidazole concentrations during oral and intravenous therapy for antibiotic associated colitis due to Clostridium difficile

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2007.01539.X

Toxin binding of tolevamer, a polyanionic drug that protects against antibiotic-associated diarrhea

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2007.01539.X

In vitro and in vivo activities of nitazoxanide against Clostridium difficile

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2007.01539.X

Nitazoxanide for the treatment of Clostridium difficile colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2007.01539.X

In vitro activity of ramoplanin against Clostridium difficile, including strains with reduced susceptibility to vancomycin or with resistance to metronidazole

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2007.01539.X

In vitro activity of rifaximin, metronidazole and vancomycin against Clostridium difficile and the rate of selection of spontaneously resistant mutants against representative anaerobic and aerobic bacteria, including ammonia-producing species

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2007.01539.X

Intravenous immunoglobulin for the treatment of severe, refractory, and recurrent Clostridium difficile diarrhea

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2007.01539.X

Descriptive study of intravenous immunoglobulin for the treatment of recurrent Clostridium difficile diarrhoea

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2007.01539.X

Active and passive immunization against Clostridium difficile diarrhea and colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2007.01539.X

Toxin production by an emerging strain of Clostridium difficile associated with outbreaks of severe disease in North America and Europe

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2007.01539.X

10.1111/J.1572-0241.2007.01539.X

21 January 2018

Identifiers

DOI

1 reference

20 September 2017

1 reference